The startup, born from the nonprofit Accumulus Synergy last August, has built a Network that connects pharmaceutical and biotechnology companies. to regulators from more than 70 countries. The new Connector makes that network accessible without abandoning the systems that companies already use.
Getting a drug approved in multiple countries simultaneously requires submitting the same information to dozens of different national regulatory authorities, each with their own systems, formats and timelines.
For most pharmaceutical and biotech companies, that process involves manual reconciliation between internal systems, significant duplication of effort, and a submission schedule that goes well beyond what the underlying science should require.
Accumulus Technologies, a San Francisco-based SaaS company created last August by Accumulus Synergy, a regulatory technology nonprofit, has been building a cloud platform to address exactly that bottleneck. Today he launched the Accumulation connectora new capability designed to make that platform accessible directly from the systems companies already use.
The 💜 of EU technology
The latest rumors from the EU tech scene, a story from our wise founder Boris and some questionable AI art. It’s free, every week, in your inbox. Sign up now!
The core of Accumulus Technologies’ offering is its regulatory network: a live platform connected to more than 70 national regulatory authorities, compared to the more than 60 countries the system covered at the time of the August 2025 spin-off.
Pharmaceutical and biotech companies use the platform to manage simultaneous filings across jurisdictions, enabling what the industry calls “pathway dependency,” a mechanism by which regulators in one country can leverage the review work of a regulator in another, shortening the time it takes for a therapy to reach patients in otherwise non-prioritized markets.
The Sanofi case announced in November 2024, while the platform was still part of Accumulus Synergy, illustrated the practical application: filings from multiple regulators managed simultaneously through a single interface rather than coordinated separately in each jurisdiction.
The Connector extends that network to a new layer of integration. Previously, use of the Accumulus platform required companies to work within the platform itself, with data moving between it and their own systems of record through manual reconciliation or custom integration work.
The Connector makes the network directly accessible from existing systems, ERP platforms, regulatory information management systems, document management tools, moving data bidirectionally between them and the regulatory network in real time.
Chanille Juneau, chief product and technology officer, described the design intent as meeting organizations “where they are,” without requiring them to move away from established infrastructure. The Connector is available to existing subscribers of the Accumulus platform.
The company is also positioning the integration layer to work in both directions: not only do pharmaceutical companies connect their systems to regulators, but regulators also connect their own systems to the Accumulus platform, creating what it describes as a “two-way network between industry and authorities.”
Accumulus Technologies is a young business entity, formally separating from Accumulus Synergy just eight months ago, although the platform it markets launched in February 2024 and the underlying nonprofit had been building the ecosystem for several years prior, backed by founding sponsors from major global pharmaceutical companies.
Francisco Nogueira, who built the platform from Accumulus Synergy, serves as CEO. The launch of Connector is the company’s first major platform capability announcement since the spinoff, and reflects the central tension in its business model: selling SaaS infrastructure to an industry that is structurally conservative, deeply regulated, and has historically treated data sharing between companies and regulators as a domain sensitive enough to require a nonprofit intermediary to build the fiat infrastructure first.
